1. W.H. Geerts, J.A. Heit, G.P. Clagett, G.F. Pineo, C.W. Colwell, F.A. Anderson, H.B. Wheeler. Prevention of Venous Thromboembolism. Chest 2001; 119: 132S-175S.
2. D.L. Diuguid. Choosing a Parenteral Anticoagulant Agent. New Engl J Med 2001; 345: 1340-1341.
3. B.I. Eriksson, K.A. Bauer, M.R. Lassen, A.G.G. Turpie, for the Steering Committee of the Pentasaccharide in Hip-Fracture Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. New Engl J Med 2001; 345: 1298-1304.
4. K.A. Bauer, B.I. Eriksson, M.R. Lassen, A.G.G. Turpie, for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. New Engl J Med 2001; 345: 1305-1310.
5. M.R. Lasssen. The EPHESUS Study: comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolysm (VTE) after elective hip replacement surgery. Blood 2000; 96: 490a.
6. A. G. Turpie. The PENTATHLON 2000 Study: comparison of the first of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolysm (VTE) after elective hip replacement surgery. Blood 2000; 96: 491a.
7. A.G.Turpie. Setting a standard for venous thromboembolism prophylaxis. Am J Health Syst Pharm 2001; 58, suppl. 2: S18-23.
8. G. Guyatt, H. Schunemann, D. Cook, R. Jaeschke, S. Pauker, H. Bucher. Grades of Recommendations for Antithrombotic Agents. Chest 2001; 119: 3S-7S.